CrAg lateral flow assay for cryptococcosis

Expert Opinion on Medical Diagnostics

Volumn 6, Issue 3, 2012, Pages 245-251

  Kozel, Thomas R ^a   Bauman, Sean K ^b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b IMMY   (United States)

Author keywords

CrAg; Cryptococcosis; Lateral flow immunochromatographic assay

Indexed keywords

ANTIRETROVIRUS AGENT; CRYPTOCOCCUS ANTIGEN; FUNGUS ANTIGEN; UNCLASSIFIED DRUG;

CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID ANALYSIS; CRYPTOCOCCAL ANTIGEN LATERAL FLOW IMMUNOASSAY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOASSAY; LATEX AGGLUTINATION TEST; NONHUMAN; PULMONARY CRYPTOCOCCOSIS; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 84860237473     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2012.681300     Document Type: Review

References (35)

1. Perfect JR. Cryptococcus neoformans. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 7th edition. Churchill Livingstone Elsever; Philadelphia, PA: 2010. p. 3287-303
2. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002;16:1031-8
3. Okongo M, Morgan D, Mayanja B, et al. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol 1998;27:698-702
4. Churchyard GJ, Kleinschmidt I, Corbett EL, et al. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000;4:705-12
5. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009;23:525-30
6. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007;45:76-80
7. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008;46:1694-701
8. Lessells RJ, Mutevedzi PC, Heller T, Newell ML. Poor long-term outcomes for cryptococcal meningitis in rural South Africa. S Afr Med J 2011;101:251-2
9. WHO Cryptococcal Guideline Working Group. Rapid advice: Diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. WHO Press, World Health Organization 2011. Available from: http://whqlibdoc.who.int/ publications/2011-9789241502979-eng. Pdf
10. Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 2011;53:321-5
11. UNICEF/UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases. Sexually Transmitted Diseases Diagnostic Initiative (SDI). World Health Organization 2009. Available from: www.who.int/std-diagnostics
12. Girosi F, Olmsted SS, Keeler E, et al. Developing and interpreting models to improve diagnostics in developing countries. Nature 2006;444(Suppl 1):3-8
13. Litvintseva AP, Xu J, Mitchell TG. Population structure and ecology of Cryptococcus neoformans and Cryptococcus gattii. In: Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A, editors. Cryptococcus: from Human Pathogen to Model Yeast. ASM Press; Washington, DC: 2011. p. 97-111
14. Dromer F, Mathoulin S, Dupont B, et al. Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. French Cryptococcosis Study Group.Clin Infect Dis 1996;23:91-6
15. Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol1984;120:123-30
16. Karstaedt AS, Crewe-Brown HH, Dromer F. Cryptococcal meningitis caused by Cryptococcus neoformans var. gattii, serotype C, in AIDS patients in Soweto, South Africa. Med Mycol 2002;40:7-11
17. Litvintseva AP, Thakur R, Reller LB, Mitchell TG. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in Sub-Saharan Africa. J Infect Dis 2005;192:888-92
18. Thakur R, Steele KT, Nthobatsang R, et al. Prevalence of C. neoformans and C. gattii among patients with cryptococcal meningitis at a tertiary hospital in Gaborone, Botswana: March 2005-February 2007, [abstract 1048]. Abst 47th Annual Meeting IDSA; Philadelphia, PA; 2009
19. Vanselow M, Brandt ME, Park BJ. Diagnosis and management of cryptococcal disease in resource-limited settings. Curr Fungal Infect Rep 2012;6:35-40
20. Gordon MA, Vedder DK. Serologic tests in diagnosis and prognosis of cryptococcosis. Am Med Assoc 1966;197:961-7
21. Gade W, Hinnefeld SW, Babcock LS, et al. Comparison of the PREMIER cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens. J Clin Microbiol 1991;29:1616-19
22. Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 2011;53:1019-23
23. Micol R, Lortholary O, Sar B, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 2007;45:555-9
24. Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009;48:856-62
25. Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count
26. Micol R, Tajahmady A, Lortholary O, et al. Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One 2010;5:e13856
27. Kozel TR, Thorkildson P, Percival A. Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen. Clin Vaccine Immunol 2011;18:1292-6
28. Kozel T, Bauman S. New developments in diagnosis: toward a point of care test. Presented at: 8th International Conference on Cryptococus and Cryptococcosis; Charleston, SC; 2011
29. Yoo SD, Worodria W, Med M, et al. The prevalence and clinical course of HIV-associated pulmonary cryptococcosis in Uganda. J Acquir Immune Defic Syndr 2010;54:269-74
30. Jarvis JN, Wainwright H, Harrison TS, et al. Pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences. Int J Infect Dis 2010;14S:e310-12
31. Brizendine KD, Baddley JW, Pappas PG. Pulmonary cryptococcosis. Semin Respir Crit Care Med 2011;32:727-34
32. Driver JA, Saunders CA, Heinze-Lacey B, Sugar AM. Cryptococcal pneumonia in AIDS: is cryptococcal meningitis preceded by clinically recognizable pneumonia? J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:168-71
33. Harris JR, Lindsley MD, Henchaichon S, et al. High prevalence of cryptococcal infection among HIV-infected patients hospitalized with pneumonia in Thailand. Clin Infect Dis 2012;54:e43-50
34. Rolfes M, Butler E, von Hohenberg M, et al. Paper #953 - Evaluation of a novel point-of-care lateral flow assay to detect cryptococcal antigen in plasma and CSF. 19th Conference on Retroviruses and Opportunistic Infections (CROI) 2012; Available from: http://www. retroconference.org/2012b/Abstracts/ 44439.htm
35. Centers for Disease Control and Prevention. Fighting a deadly fungus: A new strategy to reduce deaths due to Cryptococcus. National Center for Emerging & Zoonotic Infectious Diseases 2011. Available from: http:// www.cdc.gov/ncezid/dfwed/factsheets/ factsheet-cryptococcus-revised%205-17- 2011.pdf